Bayer’s Supreme Court Breakthrough Is Real — But the Cash Flow Math Isn’t Fixed Yet
27.06.2026 - 11:44:58 | boerse-global.de
A single ruling from the US Supreme Court on 25 June 2026 has recast the investment case for Bayer. The 7-2 decision, which held that federal pesticide law pre-empts state-level cancer warning requirements for glyphosate, knocked out the legal foundation of thousands of Roundup lawsuits. The stock responded with a 23% weekly surge to €46.61, a 78% gain over twelve months and a whisker (6.7%) below the 52-week high of €49.93.
Yet for all the euphoria, the company’s balance sheet remains under pressure. Free cash flow is still negative, net debt is elevated, and the pharmaceutical division is grappling with patent expiries on blockbusters like Xarelto — where more than 50 generics are already eating market share in Latin America. The rally has driven the 14-day relative strength index to 80.6, deep into overbought territory, while annualised volatility sits near 58%. Traders have pushed the stock 22.9% above its 50-day moving average of €37.93, a gap that historically foreshadows sharp consolidations.
Legal relief buys time, but not a clean balance sheet
The Supreme Court’s interpretation of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) effectively eliminates the bulk of claims arguing that Bayer failed to warn users about cancer risks. The company had already won 17 of the last 25 trials, and the ruling cements that winning streak. Provisions related to Roundup stood at €9.6 billion, and the decision reduces the need to set aside more cash for future settlements.
Analysts reacted quickly. DZ Bank raised its fair value estimate to €54, Jefferies lifted its price target to €46 (now surpassed by the current share price), and UBS maintained a “Buy” rating with a €52 target. The freed-up capital, in theory, could be redirected to research — particularly in biopharmaceuticals where drugs like Darolutamide and Finerenone offer growth in Latin America and beyond.
Should investors sell immediately? Or is it worth buying Bayer?
The Missouri hearing is the next pressure point
The dismissal of state-level warning claims does not end the litigation. Roughly 65,000 plaintiffs were still waiting for resolution at the end of 2025, and Bayer is pursuing a previously agreed settlement worth $7.25 billion. A final approval hearing in Missouri is scheduled for early July, though reports suggest it could be postponed. Any delay or negative outcome would reintroduce uncertainty and test the rally’s staying power.
Operationally, the turnaround story is far from proven. The pharmaceutical pipeline needs to offset looming patent losses, and the agrochemical division faces its own regulatory headwinds in the European Union. The company’s negative free cash flow remains a structural concern that no courtroom victory can instantly cure.
Two catalysts will determine whether the rally has legs
The first test comes in early July with the Missouri hearing. A smooth approval would clear the last major legal hurdle and could push the stock toward the €49.93 peak, a gain of roughly 7% from current levels. A setback, by contrast, would likely trigger profit-taking in a market already flashing technical warning lights.
Bayer at a turning point? This analysis reveals what investors need to know now.
The second catalyst is the second-quarter earnings release on 3 August 2026. Management under CEO Bill Anderson needs to prove that the operational inflection point is real — specifically by showing improvements in free cash flow and debt reduction. In the second half of the year, a detailed strategic update is planned, which will give investors a clearer view of how Bayer intends to allocate the legal savings and restore investor confidence.
For now, the market is pricing relief rather than recovery. The Supreme Court victory has removed a major overhang, but the next few weeks will determine whether the stock can sustain its newfound altitude or whether gravity reasserts itself through a combination of overbought conditions and unresolved operational challenges.
Ad
Bayer Stock: New Analysis - 27 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
